Can montelukast 10 mg once daily cause thrombocytopenia?

Montelukast Can Cause Thrombocytopenia, Though It Is Not Listed as a Common or Well-Documented Adverse Effect

Based on the FDA prescribing information and available evidence, thrombocytopenia is not identified as a recognized adverse effect of montelukast 10 mg once daily. The FDA drug label does not list thrombocytopenia among the documented hematologic adverse reactions associated with montelukast 1.

Evidence from FDA Labeling

The FDA prescribing information for montelukast provides extensive pharmacokinetic, safety, and adverse event data but does not mention thrombocytopenia as a known side effect 1. The drug label details:

• Drug interactions and metabolic pathways (primarily CYP3A4 and 2C9)
• Effects on peripheral blood eosinophil counts (9-15% decrease in asthma patients)
• Common adverse effects including neuropsychiatric symptoms (which led to FDA boxed warnings)
• No documentation of platelet-related toxicity

Clinical Context and Monitoring

While the provided evidence does not establish a link between montelukast and thrombocytopenia, it's important to note:

• The FDA issued a boxed warning for montelukast in March 2020 regarding serious neuropsychiatric events (anxiety, depression, sleep disturbances, suicidal ideation), particularly in children and adolescents 2, 3
• Current guidelines position montelukast as an alternative or add-on controller rather than first-line therapy for asthma 2
• The drug is generally well-tolerated with adverse drug reactions occurring in only 14 out of 6,158 patients in one large real-world study, with no serious adverse events reported 4

Practical Implications

If a patient on montelukast develops thrombocytopenia:

1. Consider alternative etiologies first - investigate other medications, underlying conditions, or concurrent illnesses that commonly cause low platelets
2. Review the complete medication list - the evidence provided discusses thrombocytopenia extensively in the context of tyrosine kinase inhibitors (dasatinib, imatinib, nilotinib) used for chronic myelogenous leukemia, not montelukast 5, 6, 7
3. Montelukast discontinuation may be considered if no other cause is identified, though this would represent an idiosyncratic reaction rather than a known drug effect

Important Caveat

The absence of thrombocytopenia in the FDA label and published literature does not definitively exclude the possibility of rare, idiosyncratic hematologic reactions. Post-marketing surveillance continues to identify uncommon adverse effects not detected in clinical trials. However, based on current evidence, thrombocytopenia should not be considered an expected or documented adverse effect of montelukast therapy.